Richard Carvajal

Title: Richard Carvajal: Innovator in Cancer Treatment

Introduction

Richard Carvajal is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of cancer research, particularly in the development of biomarkers for treatment resistance. His work focuses on improving therapeutic strategies for patients suffering from cancer.

Latest Patents

Richard Carvajal holds a patent for "DDX43 as a biomarker of resistance to MEK1/2 inhibitors." This invention relates to methods and compositions for determining the likelihood that a subject suffering from cancer will benefit from treatment with a MEK inhibitor. The invention is based on discoveries that DDX43 mRNA and protein are expressed at high levels in biopsies from 'non-responder' uveal melanoma patients. It was found that selumetinib-resistant cell lines showed high DDX43 expression, which correlated with increased expression and activity of RAS. The invention also suggests alternative strategies for treating cancer patients with acquired resistance to MEK inhibitors.

Career Highlights

Richard Carvajal is affiliated with Memorial Sloan Kettering Cancer Center, where he conducts research and develops innovative treatment methods. His work has been instrumental in advancing the understanding of cancer resistance mechanisms and improving patient outcomes.

Collaborations

Richard collaborates with esteemed colleagues such as Grazia Ambrosini and Raya Khanin. Their combined expertise contributes to the ongoing research and development of effective cancer treatments.

Conclusion

Richard Carvajal is a key figure in cancer research, with a focus on developing innovative solutions for treatment resistance. His contributions through patents and collaborations continue to impact the field significantly.